1. Home
  2. KROS vs RYI Comparison

KROS vs RYI Comparison

Compare KROS & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • RYI
  • Stock Information
  • Founded
  • KROS 2015
  • RYI 1842
  • Country
  • KROS United States
  • RYI United States
  • Employees
  • KROS N/A
  • RYI N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • RYI Metal Fabrications
  • Sector
  • KROS Health Care
  • RYI Industrials
  • Exchange
  • KROS Nasdaq
  • RYI Nasdaq
  • Market Cap
  • KROS 589.8M
  • RYI 661.1M
  • IPO Year
  • KROS 2020
  • RYI N/A
  • Fundamental
  • Price
  • KROS $11.84
  • RYI $21.65
  • Analyst Decision
  • KROS Buy
  • RYI Hold
  • Analyst Count
  • KROS 11
  • RYI 1
  • Target Price
  • KROS $45.33
  • RYI $28.00
  • AVG Volume (30 Days)
  • KROS 2.1M
  • RYI 209.6K
  • Earning Date
  • KROS 02-26-2025
  • RYI 02-20-2025
  • Dividend Yield
  • KROS N/A
  • RYI 3.47%
  • EPS Growth
  • KROS N/A
  • RYI N/A
  • EPS
  • KROS N/A
  • RYI 0.64
  • Revenue
  • KROS $651,000.00
  • RYI $4,703,700,000.00
  • Revenue This Year
  • KROS $303.27
  • RYI N/A
  • Revenue Next Year
  • KROS N/A
  • RYI $1.76
  • P/E Ratio
  • KROS N/A
  • RYI $33.99
  • Revenue Growth
  • KROS 8037.50
  • RYI N/A
  • 52 Week Low
  • KROS $9.78
  • RYI $17.18
  • 52 Week High
  • KROS $73.00
  • RYI $36.15
  • Technical
  • Relative Strength Index (RSI)
  • KROS 24.87
  • RYI 60.38
  • Support Level
  • KROS $10.95
  • RYI $20.04
  • Resistance Level
  • KROS $11.63
  • RYI $21.15
  • Average True Range (ATR)
  • KROS 0.87
  • RYI 0.75
  • MACD
  • KROS 1.31
  • RYI 0.44
  • Stochastic Oscillator
  • KROS 30.60
  • RYI 98.03

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority is from the United States.

Share on Social Networks: